Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes
Access status:
Open Access
Type
ArticleAuthor/s
Tan, RHKril, JJ
Yang, Y
Tom, N
Hodges, JR
Villemagne, VL
Rowe, CC
Leyton, CE
Kwok, JBJ
Ittner, LM
Halliday, GM
Abstract
The diagnostic utility of in vivo amyloid β (Aβ) imaging to aid in the clinical distinction between frontotemporal dementia (FTD) and Alzheimer's disease remains unclear without data on the prevalence and severity of Aβ in pathologically confirmed FTD syndromes.The diagnostic utility of in vivo amyloid β (Aβ) imaging to aid in the clinical distinction between frontotemporal dementia (FTD) and Alzheimer's disease remains unclear without data on the prevalence and severity of Aβ in pathologically confirmed FTD syndromes.
See less
See less
Date
2017-05-29Publisher
Alzheimer's & Dementia: Diagnosis, Assessment & Disease MonitoringLicence
CC BY-NC-ND licenseCitation
Tan RH, Kril JJ, Yang Y, et al. Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes. Alzheimers Dement (Amst). 2017;9:10-20. Published 2017 May 29. doi:10.1016/j.dadm.2017.05.005Subjects
NeuropathologyShare